IMARA(IMRA) - 2025 Q4 - Annual Results

Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Reported positive initial Phase 1b data for ELVN-001 in CML Exhibit 99.1 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Key data readout, regulatory interactions, and operational catalysts throughout 2026 Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the fir ...